Who should not take IGF-1 LR3?
Documented caution flags for IGF-1 LR3 include active malignancy (real concern with IGF-1) and diabetic retinopathy. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for IGF-1 LR3 is limited.
Documented caution flags for IGF-1 LR3
- Active malignancy (real concern with IGF-1)
- Diabetic retinopathy
- Pregnancy / nursing
- Hypoglycemia-prone
Reported side effects to weigh
- Hypoglycemia (low blood sugar), eat carbs near dose
- Localized growth at injection site
- Theoretical: visceral organ growth at chronic high doses
- Headache
References
- IGF-I and its analogs in clinical use — Clemmons DR, Endocrinol Metab Clin North Am, 2012
- Detection of His-tagged Long-R3-IGF-I in a black market product — Kohler M, Thomas A, Walpurgis K, et al., Growth Hormone & IGF Research, 2010
- Site-specific fluorescent derivatization and liquid chromatographic-mass spectrometric characterization of long R(3) IGF-I for bioanalytical applications — Harvey MD, Banks PR, Journal of Chromatography B, 2003
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on IGF-1 LR3
Last updated 2026-06-15.